Evidence map›Paper›PMID 22961865›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2012

Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis.

Sebastian Rehberg, Yusuke Yamamoto, Linda Sousse, Eva Bartha, Collette Jonkam, Anthony K Hasselbach, Lillian D Traber, Robert A Cox, Martin Westphal, Perenlei Enkhbaatar and 1 more

Abstract readComparative Study
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Selepressin, a novel selective vasopressin VCritical care (London, England) · 2017
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. HMGB1 as a drug target in staphylococcal pneumonia.Critical care (London, England) · 2014
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sebastian RehbergInvestigational Intensive Care Unit, Department of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA. Sebastian.Rehberg@ukmuenster.de
Yusuke Yamamoto
Linda Sousse
Eva Bartha
Collette Jonkam
Anthony K Hasselbach
Lillian D Traber
Robert A Cox
Martin Westphal
Perenlei Enkhbaatar
Daniel L Traber
The University of Texas Medical Branch at Galveston · USShriners Hospitals for Children - Galveston · USUniversity of Münster · DE

Funding

Role of Ventilator Damage Inflammation in Burn and Inhalation Injury/Project 4P01GM066312 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI TRABER, DANIEL L · 2004 to 2009
$7.9M
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic OptionsR01GM097480 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENKHBAATAR, PERENLEI · 2012 to 2022
$2.7M
THE ROLE OF SELECTINS IN BURNS AND INHALATION INJURYR01GM060688 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI TRABER, DANIEL L · 2000 to 2009
$2.6M
NIGMS NIH HHS GM060688NIGMS NIH HHS GM066312NIGMS NIH HHS R01 GM097480
6 · The paper itself

Abstract

Vasopressin analogs are used as a supplement to norepinephrine in septic shock. The isolated effects of vasopressin agonists on sepsis-induced vascular dysfunction, however, remain controversial. Because V(2)-receptor stimulation induces vasodilation and procoagulant effects, a higher V(1a)- versus V(2)-receptor selectivity might be advantageous. We therefore hypothesized that a sole, titrated infusion of the selective V(1a)-agonist Phe(2)-Orn(8)-Vasotocin (POV) is more effective than the mixed V(1a)-/V(2)-agonist AVP for the treatment of vascular and cardiopulmonary dysfunction in methicillin resistant staphylococcus aureus pneumonia-induced, ovine sepsis. After the onset of hemodynamic instability, awake, chronically instrumented, mechanically ventilated, and fluid resuscitated sheep were randomly assigned to receive continuous infusions of either POV, AVP, or saline solution (control; each n = 6). AVP and POV were titrated to maintain mean arterial pressure above baseline - 10 mmHg. When compared with that of control animals, AVP and POV reduced neutrophil migration (myeloperoxidase activity, alveolar neutrophils) and plasma levels of nitric oxide, resulting in higher mean arterial pressures and a reduced vascular leakage (net fluid balance, chest and abdominal fluid, pulmonary bloodless wet-to-dry-weight ratio, alveolar and septal edema). Notably, POV stabilized hemodynamics at lower doses than AVP. In addition, POV, but not AVP, reduced myocardial and pulmonary tissue concentrations of 3-nitrotyrosine, VEGF, and angiopoietin-2, thereby leading to an abolishment of cumulative fluid accumulation (POV, 9 ± 15 ml/kg vs. AVP, 110 ± 13 ml/kg vs. control, 213 ± 16 ml/kg; P < 0.001 each) and an attenuated cardiopulmonary dysfunction (left ventricular stroke work index, PaO(2)-to-FiO(2) ratio) versus control animals. Highly selective V(1a)-agonism appears to be superior to unselective vasopressin analogs for the treatment of sepsis-induced vascular dysfunction.

Indexed as

Angiopoietin-2AnimalsArginine VasopressinArterial PressureBlood VesselsCapillary PermeabilityDisease Models, AnimalFemaleHemodynamicsInfusions, IntravenousMethicillin-Resistant Staphylococcus aureusNeutrophil InfiltrationNitric OxidePneumonia, StaphylococcalReceptors, VasopressinSepsis3-nitrotyrosineAngiopoietin-2Arginine VasopressinNitric OxideReceptors, VasopressinTyrosineVascular Endothelial Growth Factor AVasoconstrictor AgentsVasotocinvasotocin, Phe(2)-Orn(8)-

Identifiers

PMID22961865
PMCPMC3517638
OpenAlexW2136505824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.